Medication info
Amozartan XQ Tablet 5/100/20/10 Milligrams

Amozartan XQ Tablet 5/100/20/10 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletEzetimibe›10mg / 1 tabletAmlodipine Besylate›6.94mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Brownish-red oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP×3]
Approval status
Active

MFDS item code 202007695 · Approved 2020.11.09 · Insurance code 643508380

Summary

Main use
Treatment of hypertension and dyslipidemia (hypercholesterolemia, etc.)
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/losartan combination and the rosuvastatin/ezetimibe combination. The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Swallow the tablet whole without chewing, dividing, or crushing it. ○ Amlodipine/losartan combination The recommended dose of the amlodipine/losartan combination is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering the amlodipine/losartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or losartan). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/losartan combination may be considered as follows. - 5/50 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 50 mg monotherapy. - 5/100 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 100 mg monotherapy. Before administering the amlodipine/losartan combination as initial therapy to patients with stage 2 hypertension, the decision to administer it should take into account baseline blood pressure, target blood pressure, and the anticipated likelihood of achieving the treatment goal with the combination compared with a single agent. The usual dose is amlodipine/losartan 5/50 mg once daily. If blood pressure is not adequately controlled after 2 weeks of treatment, the dose may be increased to 10/50 mg once daily. ∘ Patients with renal impairment: Dose adjustment is not required in patients with mild renal impairment; however, use of the amlodipine/losartan combination is not recommended in patients with moderate renal impairment. ∘ Patients with reduced intravascular volume: Use of the amlodipine/losartan combination is not recommended in a small number of patients with reduced intravascular volume (e.g., patients receiving high-dose diuretics). (See section 1, Warnings, under Precautions for Use.) ∘ Patients with hepatic impairment: Use of the amlodipine/losartan combination is not recommended in patients with a history of hepatic impairment who require a reduced dose of losartan (e.g., 25 mg once daily). ∘ Older adults: In older adults aged 75 years or over, an initial losartan dose of 25 mg once daily is recommended; therefore, use of the amlodipine/losartan combination as initial therapy is not recommended. ○ Rosuvastatin/ezetimibe combination The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue to follow a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response to treatment. Primary hypercholesterolemia The dosage range of the rosuvastatin/ezetimibe combination is 5/10 mg to 20/10 mg once daily. The recommended initial dose is 5/10 mg once daily. The dose may be adjusted for patients who require a greater reduction in LDL cholesterol. After starting the rosuvastatin/ezetimibe combination or adjusting the dose, check blood lipid levels at intervals of at least 4 weeks and adjust the dose accordingly; the dose may be increased to a maximum of 20/10 mg once daily. Patients taking the amlodipine/losartan combination together with the rosuvastatin/ezetimibe combination may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia (hypercholesterolemia, etc.)

  • Essential hypertension
  • Stage 2 hypertension
  • primary hypercholesterolemia
  • familial heterozygous hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • elevated total cholesterol
  • elevated LDL cholesterol
  • elevated Apo B protein
  • elevated triglycerides
  • elevated non-HDL cholesterol
View approved original text

This medication is used for patients who need to treat both hypertension and dyslipidemia simultaneously. Amlodipine and losartan combination is administered as initial combination therapy for patients with essential hypertension who have difficulty controlling blood pressure with monotherapy or for Stage 2 hypertension patients. Additionally, the rosuvastatin and ezetimibe combination improves cholesterol and triglyceride levels in patients with primary hypercholesterolemia and mixed dyslipidemia, helping to increase good cholesterol (HDL-C). This medication is used alongside appropriate dietary measures and is administered considering various risk factors among patients needing lipid control. Furthermore, before administering the combination therapy, it is crucial to thoroughly identify the underlying causes of dyslipidemia and treat if necessary. For these reasons, this medication is used for effective management of hypertension and dyslipidemia.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/losartan combination and the rosuvastatin/ezetimibe combination. The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Swallow the tablet whole without chewing, dividing, or crushing it. ○ Amlodipine/losartan combination The recommended dose of the amlodipine/losartan combination is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering the amlodipine/losartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or losartan). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/losartan combination may be considered as follows. - 5/50 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 50 mg monotherapy. - 5/100 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 100 mg monotherapy. Before administering the amlodipine/losartan combination as initial therapy to patients with stage 2 hypertension, the decision to administer it should take into account baseline blood pressure, target blood pressure, and the anticipated likelihood of achieving the treatment goal with the combination compared with a single agent. The usual dose is amlodipine/losartan 5/50 mg once daily. If blood pressure is not adequately controlled after 2 weeks of treatment, the dose may be increased to 10/50 mg once daily. ∘ Patients with renal impairment: Dose adjustment is not required in patients with mild renal impairment; however, use of the amlodipine/losartan combination is not recommended in patients with moderate renal impairment. ∘ Patients with reduced intravascular volume: Use of the amlodipine/losartan combination is not recommended in a small number of patients with reduced intravascular volume (e.g., patients receiving high-dose diuretics). (See section 1, Warnings, under Precautions for Use.) ∘ Patients with hepatic impairment: Use of the amlodipine/losartan combination is not recommended in patients with a history of hepatic impairment who require a reduced dose of losartan (e.g., 25 mg once daily). ∘ Older adults: In older adults aged 75 years or over, an initial losartan dose of 25 mg once daily is recommended; therefore, use of the amlodipine/losartan combination as initial therapy is not recommended. ○ Rosuvastatin/ezetimibe combination The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue to follow a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response to treatment. Primary hypercholesterolemia The dosage range of the rosuvastatin/ezetimibe combination is 5/10 mg to 20/10 mg once daily. The recommended initial dose is 5/10 mg once daily. The dose may be adjusted for patients who require a greater reduction in LDL cholesterol. After starting the rosuvastatin/ezetimibe combination or adjusting the dose, check blood lipid levels at intervals of at least 4 weeks and adjust the dose accordingly; the dose may be increased to a maximum of 20/10 mg once daily. Patients taking the amlodipine/losartan combination together with the rosuvastatin/ezetimibe combination may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication may cause serious harm to the fetus and newborn if administered to pregnant women; therefore, it should be discontinued immediately upon confirmation of pregnancy. When first administered to patients with reduced blood volume, blood pressure may drop rapidly, so this condition should be treated before use. Rare adverse effects can lead to severe muscle complications, so patients at high risk of muscle damage from acute infections or decreased kidney function should temporarily discontinue or stop taking this medication. Patients allergic to any components contained in this medication, those with certain hereditary diseases, women who are pregnant or may become pregnant, and patients with severe liver or kidney dysfunction should not use this medication. Elderly patients, those with low blood pressure, high potassium levels, heart valve disease, or renal artery stenosis should use this medication cautiously, as it may lead to excessively low blood pressure or worsening kidney function. If symptoms like myalgia or muscle weakness appear, inform a doctor immediately, and if required, check for muscle damage through blood tests. This medication may affect liver function; therefore, patients with a history of liver disease or abnormal liver function test results should undergo regular liver function tests before and during treatment. Due to the blood pressure-lowering effect, dizziness or drowsiness may occur, requiring caution when driving or operating machinery. Interactions may occur when taken with other medications, so patients should inform their doctor or pharmacist of any other medications being taken. During treatment with this medication, regular blood tests and physical examinations to monitor for adverse reactions are important.

Side effects

Craniosynostosis, anuria, hypotension, renal failure, elevated ALT, elevated AST, dermatitis, orthostatic dizziness, total renal failure, rhabdomyolysis, pancreatic carcinoma, facial swelling, strange sensations, drug intolerance, colon polyps, irritable bowel syndrome, esophagitis, dizziness, drowsiness, neurodegenerative disorders, migraines, diabetes, glucose tolerance impairment, depression, bronchitis, rhinitis, cystitis, onychomycosis, soft tissue infection, hepatic steatosis, liver dysfunction, liver toxicity, acute hepatitis, toxic hepatitis, increased gamma-glutamyl transferase, increased blood cholesterol, increased serum alkaline phosphatase, arrhythmia, osteoarthritis, osteoporosis, musculoskeletal stiffness, musculoskeletal discomfort, muscle weakness, sweating, skin burning sensation, skin disorders, alopecia, oropharyngeal pain, nasal congestion, respiratory distress, pelvic pain, breast cysts, eyelid drooping, diabetic retinopathy, ear discomfort, renal dysfunction, benign esophageal neoplasm, elevated ALT, elevated AST, dermatitis, asthenia, lethargy, pain, weight gain/loss, hypotension, vasculitis, hyperexcitability, sensory impairment, paresthesia, peripheral neuropathy, syncope, taste disturbances, tremors, erectile dysfunction, gynecomastia, changes in bowel habits, dry mouth, dyspepsia, gingival hyperplasia, pancreatitis, vomiting, hyperglycemia, arthralgia, low back pain, muscle cramps, myalgia, leukopenia, thrombocytopenia, insomnia, mood changes, cough, dyspnea, rhinitis, hair loss, increased sweating, purpura, skin discoloration, urticaria, toxic epidermal necrolysis, tinnitus, visual disturbances, increased urinary frequency, urological disorders, nocturia, hepatitis, jaundice, elevated liver enzyme levels, vascular edema, vasculitis, anaphylaxis-like syndrome, liver function abnormalities, hepatitis, intestinal vascular edema, fatigue, anemia, thrombocytopenia, myalgia, weakness, elevated creatine kinase, increased serum and urinary myoglobin, taste disturbances, dry cough, erythema multiforme, hyperkalemia, hyponatremia, syncope, loss of consciousness, acute hepatitis, fulminant hepatitis, renal failure, ventricular premature contractions, atrial fibrillation, hypoglycemia, headache, facial swelling, fever, orthostatic effect, syncope, angina, second-degree AV block, cerebrovascular accident, myocardial infarction, arrhythmias associated with atrial fibrillation, palpitations, bradycardia, tachycardia, ventricular tachycardia, ventricular fibrillation, anorexia, constipation, toothache, dry mouth, flatulence, gastritis, vomiting, anemia, gout, upper limb pain, hip joint pain, joint swelling, knee pain, musculoskeletal pain, shoulder pain, rigidity, arthralgia, arthritis, fibromyalgia, myasthenia, anxiety, anxiety disorder, ataxia, confusion, depression, nightmares, sensory reduction, decreased libido, memory impairment, migraines, neuralgias, paresthesia, peripheral neuropathy, panic disorder, sleep disorders, drowsiness, tremors, dizziness, dyspnea, bronchitis, discomfort in the pharynx, nasal bleeding, rhinitis, respiratory congestion, chest discomfort, hair loss, dermatitis, dry skin, petechial hemorrhage, erythema, flush, photosensitivity reactions, pruritus, rash, sweating, urticaria, blurred vision, burning sensation and pain in the eyes, conjunctivitis, taste disturbances, tinnitus, decreased visual acuity, erectile dysfunction, nocturia, frequent urination, urinary tract infection, renal failure, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, joint pain, fatigue, numbness, paresthesia, chest discomfort, anorexia, abdominal bloating, abnormal liver function tests, generalized edema, urticaria, hyperhidrosis, rash, pruritus, upper respiratory infection, conjunctival injection, increased serum creatinine, elevated blood pressure, increased blood urea, increased serum creatine phosphokinase, abnormal liver function tests, palpitations, dizziness, somnolence, abdominal pain, nausea, myocardial infarction, arrhythmia, chest pain, hypotension, sinoatrial block, atrioventricular block, abdominal discomfort, epigastric pain, diarrhea, loose stools, constipation, erythematous urticaria, papular rash, heaviness, heat sensation, impaired glucose tolerance, weakness, vascular edema, vasculitis, anaphylaxis-like syndrome, muscle spasms, low back pain, leg pain, myasthenia, myalgia, myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, amnesia, distal neuropathy, peripheral neuropathy, Stevens-Johnson syndrome, eosinophilia with systemic symptoms and drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, myalgia, myopathy, rhabdomyolysis, elevated liver amino transferase levels, hepatitis, abdominal pain, thrombocytopenia, nausea, dizziness, paresthesia, depression, headache, cholelithiasis, cholecystitis, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture, and maintain at room temperature between 1 degree and 30 degrees Celsius. This storage method will help preserve the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Brownish-red oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP×3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.